Background Melanoma in people of Asian descent presents primarily in non-sun-exposed
areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed …

3031 Background: Coxsackievirus A21 is an oncolytic immunotherapy consisting of a bio-
selected oncolytic strain of Coxsackievirus A21. Following intratumoral injection, preferential …

9030 Background: CVA21 (CAVATAK) is a novel bio-selected oncolytic and
immunotherapeutic strain of Coxsackievirus A21. Intratumoral (it) CVA21 injection initiates …

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57
patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this …

Abstract Background CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937)+
pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma. Methods Patients …

Purpose To compare the overall survival (OS) of patients with resected stage III melanoma
administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-α-2b) with …

Intralesional immunotherapy of melanoma has two complementary aims. One is to cause
regression of the injected metastasis. The other is to incite or modulate systemic immune …

Abstract Background: Coxsackievirus A21 (CVA21) is a novel bio-selected oncolytic,
immunotherapeutic agent. Intratumoral (it) CVA21 injection can induce selective tumor-cell …

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that
selectively infect and kill malignant cells while favoring the elicitation of a therapeutically …

Metastatic melanoma is refractory to irradiation and chemotherapy, but amenable to
immunological approaches such as immune‐checkpoint‐inhibiting antibodies or adoptive …